LCM
PBYI icon

Laurion Capital Management’s Puma Biotechnology PBYI Stock Holding History

Laurion Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-131,175
Closed -$695K – 714
2024
Q1 		$695K Hold
131,175
– – 0.01% 410
2023
Q4 		$568K Buy
+131,175
New +$435K ﹤0.01% 381
2019
Q2 		– Sell
-36,733
Closed -$1.43M – 1113
2019
Q1 		$1.43M Buy
+36,733
New +$1.12M 0.02% 455
2017
Q3 		– Sell
-66,846
Closed -$5.84M – 1832
2017
Q2 		$5.84M Buy
+66,846
New +$3.74M 0.03% 458
2016
Q4 		– Sell
-3,100
Closed -$208K – 1239
2016
Q3 		$208K Buy
+3,100
New +$157K ﹤0.01% 800
2016
Q2 		– Sell
-28,300
Closed -$831K – 974
2016
Q1 		$831K Buy
+28,300
New +$1.28M 0.01% 457

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laurion Capital Management's PBYI Position: Q2 2024 in Review

Laurion Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 131,175 shares — an estimated $695K sold.

Laurion Capital Management first reported a position in PBYI in Q1 2016 and held it in 6 quarters. The position peaked at $5.84M in Q2 2017. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Laurion Capital Management reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 131,175 Puma Biotechnology shares in Q2 2024, an estimated $695K.
  • Laurion Capital Management first reported a position in Puma Biotechnology in Q1 2016 and held it in 6 quarters.
  • Laurion Capital Management's Puma Biotechnology position peaked at $5.84M in Q2 2017.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.